Senior Director, Health Economics and Outcomes Research, International

BridgeBio is a biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients living with genetic diseases and genetically defined cancers. Since our founding in 2015, we have built a diverse portfolio of more than 20 drug development programs, ranging from early discovery to late-stage clinical trials, across multiple therapeutic areas including precision oncology, cardiology, endocrinology, neurology, and renal disease. We have already achieved regulatory approval for three therapies and continue to advance promising science from academia into meaningful treatments for patients worldwide. 

BridgeBio is a global biotechnology company with our Global Headquarters located in San Francisco, USA, and our International HQ located in Zug, Switzerland. Since establishing our European presence in 2021, we’ve been building empowered, high-performing teams across countries — with experienced colleagues who move quickly, take ownership, and are fueling the company’s international growth. 

At BridgeBio, you’ll find an energetic and collaborative culture where pragmatism meets bold decision-making. We embrace uncertainty with confidence, guided by our commitment to making a meaningful impact for patients. Our people are trusted and empowered, united by urgency, purpose, and the drive to advance science for patients around the world. 

To learn more about our story and company culture, visit us at https://bridgebio.com

You will report to the VP, Head of Market Access, International and work closely with Market Access, Medical Affairs, Commercial International, and Launch Excellence colleagues across BridgeBio’s international markets, to drive strategic initiatives that support BridgeBio’s mission of delivering transformative medicines to patients globally.

Your primary purpose will be to lead the international HEOR strategy, generating and leveraging health economic and outcomes research evidence to secure timely, sustainable patient access to the company’s products. This includes oversight of HTA submissions, value dossiers, and real-world evidence studies across multiple international markets. In this role you ensure alignment of HEOR priorities with clinical value, launch timelines, and market access strategy.

You will also be a core member of the International Market Access team, contributing HEOR and evidence-generation expertise to global decision-making and ensuring alignment across regions while representing diverse market perspectives.

This role requires strong collaboration with cross-functional colleagues and external stakeholders across multiple countries to ensure high-quality execution and impact. The ideal candidate combines deep expertise in health economics and outcomes research across several international markets and experience supporting the introduction of innovative therapies in a global biotech environment. You are eager to make a meaningful contribution in pre-launch and launch phases, particularly within rare diseases and orphan conditions, and bring strong communication skills, adaptability, and the ability to thrive in a fast-paced, hands-on environment.

• →Define and lead the international HEOR strategy, ensuring alignment with market access and launch objectives across BridgeBio's therapeutic areas
• →Design and oversee non-interventional studies, including registries and real-world evidence generation, from protocol development through publication
• →Lead early payer engagement with key HTA/payer bodies (e.g. NICE UK, G-BA Germany, HAS France) to inform evidence generation strategy and reimbursement dossier development
• →Closely collaborate with Market Access, Medical Affairs, and Commercial colleagues to ensure value and access optimization across international launches
• →Provide health economic modeling and outcomes research expertise to support pricing and reimbursement strategy
• →Manage external vendors, budgets, and contracts for HEOR studies, ensuring rigorous project management across competing deadlines

This is an office role based in our Zug Office, requiring in-office presence, with approximately 10% travel to support HTA engagements and stakeholder meetings across international markets.

• Graduate degree in health economics, epidemiology, health services research, or another research-focused public health field (PhD preferred); 9+ years of experience with an MSc/MPH, or 7+ years with a PhD, in HEOR or related fields
• Extensive experience leading HTA submissions and pricing negotiations across multiple international markets, ideally including Europe, particularly in rare diseases and orphan conditions
• Direct experience engaging with HTA organizations such as NICE, CADTH, PBAC, HAS, IQWiG/G-BA, and ICER
• Demonstrated in-depth understanding of health economic modeling, patient-reported outcomes, statistics, and real-world evidence studies, including registries and observational study design, implementation, analysis, and interpretation
• Capable of independently managing complex, multicultural, cross-functional teams and non-interventional study projects on an international basis
• Strong project management abilities, including contracting, budgeting, and vendor management, with the ability to manage competing deadlines and rapidly shifting priorities
• Comfortably influencing senior stakeholders across medical, clinical, and commercial teams, and operating effectively within a matrix organization
• International mobility and willingness to travel internationally, approximately 10% of time

We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return.

• Market leading compensation
• Hybrid work model - we value your flexibility in how you work, but encourage time in the office to strengthen our culture, collaboration, and sense of community
• We provide career development through regular feedback, continuous education and professional development programs
• We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities.